Connect with us

Globe Trotting

Bayer to invest USD 150 million to build new cell culture technology center

Bayer will invest USD 150 million in its Berkeley, CA, pharmaceutical development and manufacturing site to build a Cell Culture Technology Center that will be used to accelerate the development of biological therapies. Once complete, the new facility will support Bayer’s growing portfolio in biologics to serve multiple patient populations.

The new Cell Culture Technology Center will be built on Bayer’s existing Berkeley campus, home to its recombinant Factor-VIII manufacturing center that produces hemophilia-A treatments for patients in nearly 80 countries around the world. The new 40,000 square foot facility, which is expected to be ready for clinical production in late 2021, will support the development of emerging therapies in Bayer’s portfolio with an emphasis on oncology, cardiology, and additional specialty care therapeutic areas. The company has selected Fluor for design and construction, and GE Healthcare for the integration of its FlexFactory technology platform into the Center.

Copyright © 2024 Medical Buyer

error: Content is protected !!